d with regards to mRNA decay. U. Atasoy, J. Dobe, N. Kadouri, B. Dassa, S. Ben-Dor, in addition to a. Berger s critically evaluated the manuscript. Y. Goldfarb, E.S. Husebye, and J. Abramson wrote the manuscript. Disclosures: The authors declare no competing interests exist. Submitted: 8 June 2020 Revised: 7 February 2021 Accepted: 9 August
CB1 Formulation 282021 ten 42 ten Chin J HematolOctober 2021Vol. 42No.CYP3A() 300020 Email [email protected] CYP3AGVHD 2019 7 2020 two allo-HSCT 35 CYP3A5 MTX GVHD two 3 23 1015 ng/ml 16 CYP3A53/3 allo-HSCT 9.82 ng/ml 8.53 ng/ml / C/D 5.72 ng l-1 g-1 four.26 ng l-1 g-1 allo-HSCT C/D 5.29 ng l-1 g-1 4.61 ng l-1 g-1 five.65 ng l-1 g-1 four.56 ng l-1 g-1 19 CYP3A51 0.028 P 0.001 0.037 0.045 CYP3A51 allo-HSCT GVHD CYP3A53/3 26.30.1 6.2.1 P0.187 CYP3A5 allo-HSCT GVHD CYP3A5 81670171 82070192 Z20-15 3332020052 DOI ten.3760/cma.j.issn.0253-2727.2021.10.006 The effect of CYP3A5 gene polymorphism on tacrolimus concentration and adverse events in patients undergoing allogeneic hematopoietic stem cell transplantation Chen Xin Zhang Rongli, Zhai Weihua, Ma Qiaoling, Pang Aiming, Yang Donglin, He Yi, Wei Jialin, Jiang Erlie, Feng Sizhou, Han Mingzhe State Essential Laboratory of Experimental Hematology, National Clinical Study Center for Blood Ailments, Institute of Hematology Blood 5-HT1 Receptor web Ailments Hospital, Chinese Academy of Healthcare Sciences Peking Union Healthcare College, Tianjin 300020, China Corresponding author Jiang Erlie E mail: [email protected] Abstract Objective To investigates the partnership in between CYP3A5 gene polymorphism, tacrolimus concentration, and acute graft versus host diseaseGVHDin individuals undergoing allogeneic hematopoietic stem cell transplantationallo- HSCT Solutions A retrospective evaluation on the clinical . data of 35 Chinese adult patients who received allo-HSCT from July 2019 to February 2020 was carried out. Also, bone marrow samples have been collected before transplantation for CYP3A5 genotyping, and intravenous infusion of tacrolimus and also a short course of methotrexateMTXmycophenolate have been utilized to stop GVHD. The initial concentration was monitored around the second or third day of tacrolimus administration, followed by 2-3 occasions a week. The drug dose was adjusted based on the target blood concentration1015 ng/ml Final results In 16 allo- HSCT individuals with CYP3A5 3/3 gene, the initial concentration of . tacrolimus9.82 ng/ml vs 8.53 ng/ml the initial concentration/doseC/Dratio5.72 ng l – 1 g – 1 vs ,2021 ten 42Chin J HematolOctober 2021Vol. 42No.294.26 ng l – 1 g – 1 plus the median C/D ratio in the first two weeks following HSCT5.29 ng l – 1 g – 1 vs , four.61 ng l -1 g -1, five.65 ng l -1 g -1 vs 4.56 ng l -1 g -1were significantly higher than in 19 sufferers with a minimum of one particular CYP3A5 1 alleleP0.028, 0.001, 0.037, 0.045 The incidence of – aGVHD in . patients with CYP3A51 alleles was larger than in sufferers with CYP3A53/3 gene 26.30.1 vs 6.2 6.1 , P0.187 Conclusion CYP3A5 genotype- directed administration may perhaps enable realize the . target blood concentration of tacrolimus immediately after HSCT extra speedily, minimize the incidence of serious aGVHD, and improve the efficacy of transplantation. Crucial words CYP3A5 genotype; Tacrolimus; Blood drug concentration; Hematopoietic stem cell transplantation Fund plan: The National Organic Science Foundation of China81670171,82070192 Transla; tional medicine investigation fund of State Essential Laboratory of Experimental HematologyZ20-15 The Fun
